Nivalis Sets IPO Range

Boulder-based Nivalis Therapeutics has set its estimated initial IPO range, saying that it now expects its stock to IPO at between $13.00 and $15.00 pr share. The company is looking to raise up to $73.9M in its IPO. The company has allied to list on the NASDAQ Global Market as NVLS. Nivalis is working on cystic fibrosis drugs, and is venture backed by Deerfield Management, Wellington Management, Tiger Partners, RA Capital Healthcare Fund, as well as others. Nivalis was most recently known as N30 Pharma, before it changed its name before its IPO filing.